Ropes & Gray: In Law360, David Peloquin Discusses Impending FDA Guidance on Diversifying Clinical Trial Participation
June 06, 2024
June 06, 2024
BOSTON, Massachusetts, June 6 -- Ropes and Gray, a law firm, issued the following news:
In a Law360 article, health care partner David Peloquin commented on impending guidance from the U.S. Food and Drug Administration on diversifying clinical trial participation.
Because the efficacy and safety of treatments can vary across patient groups, many drug developers and regulators seek to include more historically underrepresented populations.
David notes it wou . . .
In a Law360 article, health care partner David Peloquin commented on impending guidance from the U.S. Food and Drug Administration on diversifying clinical trial participation.
Because the efficacy and safety of treatments can vary across patient groups, many drug developers and regulators seek to include more historically underrepresented populations.
David notes it wou . . .